Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

628
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
628
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

671
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
671
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Cross-bridge Cycle01:26

Cross-bridge Cycle

118.0K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
118.0K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Choroid plexus calcification detection using quantitative susceptibility mapping MRI.

medRxiv : the preprint server for health sciences·2026
Same author

Quantitative imaging of iron dysregulation in multiple system atrophy.

NeuroImage·2026
Same author

Associations Between Lifetime Stressor Exposure and Externalizing Problems in Youth at Risk for Huntington Disease.

Brain and behavior·2026
Same author

Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

Parent Emotion Socialization Behaviors and Adolescent Psychological Symptoms in Families Impacted by Tourette Syndrome.

Research on child and adolescent psychopathology·2026
Same author

Functional and Structural Evidence of Neurofluid Circuit Aberrations in Huntington Disease.

Annals of clinical and translational neurology·2026
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Aug 26, 2025

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

32.1K

Multiple System Atrophy.

Daniel O Claassen

    Continuum (Minneapolis, Minn.)
    |October 12, 2022
    PubMed
    Summary
    This summary is machine-generated.

    Multiple system atrophy (MSA) management requires addressing diverse symptoms and utilizing new diagnostic tools like skin biopsies and neuroimaging for earlier detection. Comprehensive care involves an interdisciplinary team approach.

    More Related Videos

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
    12:28

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

    Published on: June 3, 2020

    17.5K
    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    11.5K

    Related Experiment Videos

    Last Updated: Aug 26, 2025

    Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
    08:16

    Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

    Published on: March 4, 2014

    32.1K
    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
    12:28

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

    Published on: June 3, 2020

    17.5K
    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    11.5K

    Area of Science:

    • Neurology
    • Rare Diseases
    • Clinical Practice

    Background:

    • Multiple system atrophy (MSA) presents with varied clinical symptoms, complicating patient care.
    • Despite its rarity, MSA is frequently encountered, necessitating updated clinical strategies.
    • Advances in diagnostics and treatments are emerging for MSA.

    Purpose of the Study:

    • To summarize current treatment options for the diverse symptoms of MSA.
    • To highlight recent advancements in diagnosing and managing MSA.
    • To guide clinicians in providing comprehensive care for MSA patients.

    Main Methods:

    • Review of recent findings in biofluid biomarkers.
    • Analysis of neuroimaging techniques for MSA diagnosis.
    • Exploration of novel treatment concepts, including central noradrenergic augmentation.
    • Inclusion of skin biopsies as a diagnostic tool.

    Main Results:

    • New diagnostic assessments, including skin biopsies and neuroimaging, show promise for earlier and more accurate MSA detection.
    • Emerging treatment strategies, such as central noradrenergic augmentation, are being investigated.
    • Understanding diverse symptomatology is crucial for effective management.

    Conclusions:

    • Comprehensive care for MSA patients necessitates an interdisciplinary team.
    • A thoughtful approach to emerging symptoms and treatment decisions is vital.
    • Early and accurate diagnosis through novel biomarkers and assessments can improve patient outcomes.